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Abstract
Background: In patients with schizophrenia, early non-response to oral antipsychotic therapy robustly predicts
subsequent non-response to continued treatment with the same medication. This study assessed whether early
response predicted later response when using a long-acting injection (LAI) antipsychotic.
Methods: Data were taken from an 8-week, randomized, double-blind, placebo-controlled study of olanzapine LAI
in acutely ill patients with schizophrenia (n = 233). Early response was defined as ≥30% improvement from
baseline to Week 4 in Positive and Negative Syndrome Scale (PANSS0-6) Total score. Subsequent response was
defined as ≥40% baseline-to-endpoint improvement in PANSS0-6 Total score. Sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and predictive accuracy were calculated. Clinical and
functional outcomes were compared between Early Responders and Early Non-responders.
Results: Early response/non-response to olanzapine LAI predicted later response/non-response with high sensitivity
(85%), specificity (72%), PPV (78%), NPV (80%), and overall accuracy (79%). Compared to Early Non-responders, Early
Responders had significantly greater improvement in PANSS0-6 Total scores at all time points and greater baseline-
to-endpoint improvement in PANSS subscale scores, Quality of Life Scale scores, and Short Form-36 Health Survey
scores (all p ≤ .01). Among Early Non-responders, 20% demonstrated response by Week 8. Patients who lacked
early improvement (at Week 4) in Negative Symptoms and Disorganized Thoughts were more likely to continue
being non-responders at Week 8.
Conclusions: Among acutely ill patients with schizophrenia, early response predicted subsequent response to
olanzapine LAI. Early Responders experienced significantly better clinical and functional outcomes than Early
Non-responders. Findings are consistent with previous research on oral antipsychotics.
Clinical Trials Registry: F1D-MC-HGJZ: Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment
of Patients With Schizophrenia http://clinicaltrials.gov/ct2/show/NCT00088478?term=olanzapine+depot&rank=3
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The time-course of response to antipsychotic therapy has
been extensively evaluated, and the original belief that it
took between 6 and 8 weeks to determine a therapy’s
effectiveness in patients with schizophrenia has largely
been abandoned [1]. In many studies, most of the sympto-
matic improvement seen in response to atypical antipsy-
chotic therapy occurs in the first 2 to 4 weeks, with effects
seen in some patients in as early as 24 hours [1-3]. This
finding has important implications for the medical man-
agement of acutely ill patients with schizophrenia who,
individually, have an unpredictable response to any given
antipsychotic. When symptom improvement is minimal or
absent, adjustments in dose, delivery schedule, or drug
therapy can be made sooner than once thought. This
reduces unnecessary exposure to ineffective treatment
while effective treatment is delayed and, in addition, may
reduce the long-term clinical, functional, and economic
harm associated with inadequate treatment [4].
Recently, there has been much interest in early response
or non-response to treatment as a predictor of subsequent
response to the same treatment. Failure to respond in the
first 1 to 2 weeks of therapy has been shown to robustly
predict later failure to respond to continued use of the
same medication, a finding seen both in patients with
chronic schizophrenia [5-8]. and in patients who are early
in their course of illness [9]. Most of these analyses were
retrospective, but a recent randomized, prospective study
of early response produced similar results [7]. Although
study designs have differed, and the analyses have involved
different patient populations and utilized different defini-
tions of and time points for assessing early and later
response, the predictive power of early non-response
resulting in later non-response has been a constant. Also
constant has been the use of oral antipsychotic agents; the
predictive strength of early response to depot (injectable)
formulations has not yet been evaluated.
The trajectory of symptomatic improvement for patients
who respond early to oral antipsychotic medication clearly
differs from that of patients who do not show early
response. The early responder groups have had higher
baseline illness severity, more rapid symptom improve-
ment, and consistently greater magnitude of improvement
over time [6,7]. Investigators have identified characteristics
at baseline that differentiate these distinct responder
groups. For example, in analyses of patients with chronic
schizophrenia who were treated with oral antipsychotics,
early responders had, on average, shorter illness duration
[6].; fewer acute exacerbations of schizophrenia in the pre-
vious 24 months [7].; higher likelihood of having schizoaf-
fective disorder [6,7].; and higher Positive and Negative
Syndrome Scale (PANSS) [10]. Total,[6,7]. Positive,[6,7].
and General Psychopathology [6]. scores than Early Non-
responders. In patients with first-episode psychosis being
treated with oral antipsychotics, Early Responders had
shorter durations of illness and higher average weight at
baseline than Early Non-responders [9]. Such differences
may help clinicians optimize the initial choice of treatment
for a given patient.
Whether patients who do or do not respond early to
injectable antipsychotics differ in their functional outcomes
or sense of health status also is not known. There is evi-
dence based on analyses of response to oral antipsychotics
to suggest that differences in functional outcome may
exist. In a post hoc analysis of a 1-year, randomized, open-
label study of oral antipsychotics, patients who demon-
strated early response had greater improvement from
baseline to Week 8 in measures of mental, physical, and
functional health than those who did not respond early [4].
Similar degrees of functional improvement were also seen
in a 12-week, prospective study of early response [7].
It is not known whether the predictive power of early
response to oral antipsychotic therapy extends to long-
acting injection (LAI) antipsychotics. Olanzapine LAI has
been shown to have an early onset of action, with clinical
improvement detectable as early as the first week of treat-
ment. Although olanzapine LAI provides therapeutic drug
levels following the first injection, drug levels continue to
accumulate, reaching steady state olanzapine plasma con-
centrations approximately 3 months after initiation of
therapy [10]. Given that olanzapine LAI takes longer to
reach steady state than oral olanzapine, and given that it is
dosed as frequently as every 2 weeks and as infrequently
as every 4 weeks, it is not known what might constitute
“early” response and whether early response would be pre-
dictive of subsequent response. In addition, it is unclear
whether patients who do not initially respond to olanza-
pine LAI are likely to respond with further treatment.
B e c a u s eu s eo fo l a n z a p i n eL A Im a yh a v ei n v o l v e do v e r -
coming patient resistance to an injectable formulation, or
may be viewed as a patient’s “last resort,” it is important
not to discontinue therapy prematurely.
The primary objective of this analysis is to assess
whether response to olanzapine LAI at Week 4 of treat-
ment predicts response/non-response at Week 8 of treat-
ment in acutely ill patients with schizophrenia. Secondary
objectives include identifying baseline characteristics
that might help differentiate Early Responders from
non-responders, searching for differences in functional
outcome between Early Responders and Early Non-
responders, and identifying factors that predict later
response in those patients who do not respond early.
Methods
Patient Population and Study Design
This was a post hoc analysis of data from an 8-week, ran-
domized, double-blind trial comparing multiple dosing
regimens of olanzapine LAI with placebo for treatment
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were male or female, aged 18 to 75 years, with a diagnosis
of schizophrenia (DSM-IV or DSM-IV-TR), and a
PANSS-derived Brief Psychiatric Rating Scale (BPRS, 0-6
scale) score ≥30, reflecting a moderate-to-high level of
illness severity. Patients were excluded if they had experi-
enced serious adverse events while taking oral olanza-
pine, currently had significant suicidal or homicidal
tendencies, were currently pregnant or breast-feeding, or
had a serious or unstable medical condition in the pre-
vious 30 days. The study was conducted from June 2004
to April 2005 at multiple study sites in the United States,
Russia, and Croatia. Guidelines from the Declaration of
Helsinki were followed, the study protocol was approved
by local ethical review boards, and all patients or their
authorized representatives signed written informed
consent prior to participation in the trial (F1D-MC-
HGJZ; NCT00088478; http://clinicaltrials.gov/ct2/show/
NCT00088478?term=olanzapine+depot&rank=3).
After a 2- to 7-day screening and washout period,
patients were randomly assigned (1:1:1:1) to receive olan-
zapine LAI in doses of 210 mg/2 weeks, 300 mg/2 weeks,
405 mg/4 weeks, or placebo. Patients entered as inpati-
ents or outpatients, but were hospitalized during the
wash-out period and for the first 2 weeks of treatment. If
a patient had previously received depot antipsychotics,
the interval since the last dose had to be 3 weeks or 1
injection interval, whichever was longer. Concomitant
use of central nervous system medication was prohibited,
except for limited use of select benzodiazepines/sedatives
as needed for sleep.
Assessments and Definitions
The primary outcome was mean baseline-to-endpoint
change (last observation carried forward) in PANSS Total
score after 8 weeks of treatment. The PANSS is a 30-item
scale with each item scored between 1 (no symptoms) and
7 (severe symptoms), from which are derived a Total
score, and Positive, Negative, and General Psychopathol-
ogy subscores. The PANSS was administered at baseline,
Day 3, Day 7, and weekly thereafter. Patients were assessed
with the Short Form-36 Health Survey (SF-36) [12]. and
the Quality of Life Scale (QLS) [13]. at baseline and End-
point (Week 8). The SF-36 is a 36-item instrument for
measuring health status and outcome from the patient’s
point of view. Scoring yields 8 health scores (vitality, physi-
cal functioning, bodily pain, general health perceptions,
physical role functioning, emotional role functioning,
social role functioning, and mental health) and 2 summary
scores - the Mental composite score and the Physical
composite score. The QLS is a 21-item scale that consists
of a semi-structured interview administered by a trained
clinician and provides information on symptoms and func-
tioning during the preceding 4 weeks. Each item is scored
from 0 to 7, with the low end of the scale reflecting more
severe impairment. Scale items are grouped conceptually
to form four subscales: Intrapsychic Foundations; Interper-
sonal Relations; Instrumental Role; and Common Objects
and Activities.
“Early response” was defined as a ≥30% improvement
o v e rt h eb a s e l i n eP A N S S 0-6 Total score at Week 4, and
“later response” was defined as a ≥40% improvement over
the baseline PANSS0-6 Total score at Week 8. Using these
thresholds, patients were identified as “Early Responders”
or “Early Non-responders” and “Late Responders” or “Late
Non-responders.” As suggested by Leucht et al. [14]. we
rescaled the PANSS1-7 so that the range of scores was 0 to
6 rather than 1 to 7, such that the minimum score (ie, no
symptoms) for the PANSS0-6 was 0 rather than 30. Rescal-
ing of the PANSS1-7 prevented an underestimate of per-
centage improvement, since a 100% reduction in PANSS
score is not possible using the other scaling convention
[15].
Statistical Analysis
This analysis included the 233 patients who received olan-
zapine LAI and who had a PANSS Total score at Week 4
and at least 1 PANSS Total score after Week 4. Condi-
tional probabilities of early response (Week 4) predicting
later response (Week 8) were calculated and included
sensitivity, specificity, negative predictive value (NPV),
positive predictive value (PPV), and total accuracy. To
assess for differences between Early Responder and Early
Non-responder groups, baseline characteristics for each
group were compared using Fisher’s exact test for catego-
rical variables and t-test for continuous variables.
Least square (LS) mean change from baseline in PANSS
Total score was compared between responder groups at
each time point using a mixed model repeated measures
method with baseline PANSS Total score, investigator,
responder status, week, and responder status-by-week
interaction terms.
Baseline-to-endpoint change in the Davis factor sub-
scales of the PANSS were compared between Early
Responder and Early Non-responder groups using an ana-
lysis of covariance model that included baseline score,
investigator, and responder status. In 2001, Davis et al.
[16]. used factor analysis to assign the 30-item PANSS to
5 subscales. The “Davis subscales” are weighted sums of
specific PANSS items and include the following factors:
Positive Symptoms (P1, P2, P3, P5, P6, P14, P23, P26,
P29), Negative Symptoms (P8, P9, P10, P11, P13, P21,
P30), Disorganized Thoughts (P2, P12, P14, P18, P19, P24,
P25, P26, P27, P29), Impulsivity/Hostility (P4, P7, P22,
P28), and Anxiety/Depression (P15, P16, P17, P18, P20).
QLS measure subscores and SF-36 factor scores were
compared between Early Responder and Early Non-
responder groups using an analysis of covariance model
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pared, investigator, and responder status.
For all analyses, results were considered significant at
the p < .05 level and all statistical analyses were con-
ducted using SAS (version 8.2, Cary, NC, USA).
Results
The original study enrolled 404 patients, 306 of whom
were treated with olanzapine LAI. Of the 306 patients, 233
(76%) met eligibility criteria for this analysis. Of these
patients, 137 (58.8%) were identified as Early Responders
and 96 (41.2%) were identified as Early Non-responders.
The baseline characteristics of the Early Responder and
Early Non-responder groups are shown in Table 1. There
were no significant differences between responder groups
on any demographic variable. The majority of patients
were white, approximately one-third were female, and the
average age was close to 40 years. Differences were found
between groups regarding baseline psychopathology, with
the Early Responder group appearing more ill at baseline.
The mean PANSS Total score of Early Non-responders
exceeded that of Early Non-responders by 5 points (102.5
vs. 97.5, p < .01). A significant difference was also observed
for anxiety and depression between the Early Responder
group compared with the Early Non-responder group
(14.4 vs. 13.1, p=.005). The difference between scores for
the PANSS Negative subscale also approached significance
(24.8 for Early Responders, 23.3 for Early Non-responders;
p=.05).
Response at Week 4 predicted response at Week 8 with
a good degree of accuracy. Sensitivity was 84.9%, specifi-
city was 72.0%, PPV was 78.1%, NPV was 80.2%, and total
accuracy was 79.0% (Figure 1). Rates of study discontinua-
tion for any reason were higher for Early Non-responders
than for Early Responders (25.0% versus 17.5%, p=.007).
LS mean change from baseline in PANSS Total score for
patients identified as Early Responders and Early Non-
responders is shown in Figure 2. Early responders had sig-
nificantly greater change in PANSS Total score at every
time point (p < .001), and by Week 8, they had over twice
the reduction in LS mean PANSS Total score than Early
Non-responders had (37.0 points versus 15.4 points).
Baseline-to-endpoint LS mean change in Davis Factor
PANSS subscale scores for patients identified as Early
Responders and Early Non-responders is depicted in
Figure 3. For all 5 PANSS subscale scores - Positive,
Negative, Disorganized Thoughts, Impulsivity/Hostility,
and Anxiety/Depression - Early Responders had greater
baseline-to-endpoint improvement than Early Non-
responders at a p < .001 level of significance. For each
subscale, change in PANSS subscale for the Early
Responder group was at least double that of the Early
Non-responder group.
With regard to the patients’ sense of health status,
Early Responders had significantly more improvement in
the following LS mean SF-36 subscale scores: Mental
Component Summary (p=.01), Mental Health (p=.004),
and Social Functioning (p=.002). On the QLS, Early
Table 1 Baseline Characteristics for Responder Groups









Age, years (mean [SD]) 40.8 (11.6) 38.8 (11.1) .18
Female gender, (n [%]) 35 (25.6) 30 (31.3) .34
Race (n [%]) .75
White 81 (59.1) 55 (57.3)
African American 47 (34.3) 33 (34.4)
Hispanic 8 (5.8) 5 (5.2)
Other 1 (0.7) 3 (3.1)
Age at first schizophrenia episode, years
(mean [SD])
23.7 (7.9) 22.1 (8.7) .15
PANSS scores (mean[SD])
Total 102.5 (16.0) 97.5 (12.3) .01
Positive 27.4 (5.5) 26.4 (4.5) .14
Negative 24.8 (5.7) 23.3 (5.5) .05
Disorganized Thoughts 25.0 (5.5) 24.1 (4.2) .21
Impulsivity/Hostility 11.0 (3.5) 10.6 (3.4) .36
Anxiety/Depression 14.4 (3.6) 13.1 (3.4) .005
CGI-S mean [SD]) 4.8 (0.8) 4.7 (0.7) .20
Weight, kg (mean [SD]) 85.6 (22.2) 84.1 (19.2) .58
Abbreviations: CGI-S = Clinical Global Impression-Severity; PANSS = Positive and Negative Syndrome Scale; SD = standard deviation.
a Early response = ≥30% reduction from baseline in PANSS Total score at Week 4; later response = ≥40% reduction in PANSS Total score at Week 8.
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Early Non-responders for the Total score (p < .001) and
all subscales (Common Objects and Activities, p=.01;
Intrapsychic Foundations, p < .001; Interpersonal Rela-
tions, p < .001; and Instrumental Role, p=.004).
Of the 96 patients who did not meet criteria for
response at Week 4, 19 patients (20%) met criteria for sub-
sequent response. In the regression model, lack of
improvement in the Negative Symptom and the Disorga-
nized Thoughts factors predicted non-response at end-
point for patients who had not responded by Week 4.
Specifically, lack of at least a 3-point drop from baseline in
both of these factor scores at Week 4 predicted continued
non-response with a 48% PPV, 91% NPV, 68% sensitivity,
and 82% specificity (Figure 4). The Negative Symptom
factor includes measures of blunted affect, emotional with-
drawal, poor rapport, passive/apathetic social withdrawal,
flow of conversation, motor retardation, and active social
avoidance. The Disorganized Thoughts factor includes
assessment of conceptual disorganization, difficulty in
abstract thinking, stereotyped thinking, tension, manner-
isms and posturing, disorientation, poor attention, lack of
Figure 1 Model and conditional probabilities for early response predicting later response for patients with chronic schizophrenia.
Abbreviations: CI = confidence interval; NPV = negative predictive value; OR = odds ratio; PPV = positive predictive value. Definitions: early
response = ≥30% reduction from baseline in PANSS Total score at Week 4; later response = ≥40% reduction in PANSS Total score at Week 8.
Figure 2 Least square mean change from baseline in PANSS Total score for Responder Groups.A b b r e v i a t i o n s :P ANSS = Positive and
Negative Syndrome Scale Score. a Early response was defined as a ≥30% improvement from baseline in PANSS Total score at Week 4. b
Statistically significant within-group difference, p < .001. c Statistically significant between-group difference, p < .001.
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preoccupation.
Discussion
In this post hoc analysis of data from a randomized,
double-blind, clinical trial of olanzapine LAI for treat-
ment of acute exacerbation of schizophrenia, early
response (Week 4) was found to predict subsequent
response (Week 8) with high degrees of sensitivity,
specificity, PPV, and NPV, and an overall accuracy level
of 79%. The group of patients who met criteria for early
response had a trajectory of symptom recovery that was
distinct from that of the group who did not meet
response criteria. Compared to Early Non-responders,
Early Responders had a higher level of symptom severity
at baseline as measured by PANSS Total score, and had
a greater degree of improvement over baseline at every
subsequent time point. By Week 8, improvement by
Early Responders was more than double that of Early
Non-responders (-37 points vs. -15 points).
The total accuracy of predicting later response to
olanzapine LAI based on early response exceeded that
seen in studies of oral antipsychotics, including analyses
of patients with chronic schizophrenia,[7]. of patients
with first-episode psychosis,[9]. of a prospective study of
patients with chronic schizophrenia,[7]. and of 5 pooled
studies of patients with chronic schizophrenia [6]. (79%
for olanzapine LAI versus 72%, 70%, and 74%, respec-
tively). Much of the increase in total accuracy was due
to stronger performance for sensitivity (85% for olanza-
pine LAI versus 70%, 77%, and 60%, respectively) and
PPV (78% for olanzapine LAI versus 63%, 42%, and
54%, respectively). Stronger predictive characteristics in
this analysis may have been due to use of a later time
point to assess early response; Week 4 for this analysis
versus Week 2 in the oral olanzapine studies. Predic-
tions of later response have been shown to improve as
the time point for early assessment is delayed,[17]. and a
Figure 3 Least square baseline-to-endpoint mean change in
Davis Factor PANSS subscale scores for Responder Groups.
Abbreviations: LS = least square; PANSS = Positive and Negative
Syndrome Scale Score. a Early response was defined as a ≥30%
improvement from baseline in PANSS Total score at Week 4.
Figure 4 Conditional probabilities for predicting later response in Early Non-responder patients (N = 96). Abbreviations: CI = confidence
interval; NPV = negative predictive value; OR = odds ratio; PPV = positive predictive value. Definitions: later response = week 8; early response = week4 .
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accuracy and expedient recognition of a need to adjust
treatment. In this instance, the later time point was cho-
sen because for many of the patients in this study, 4
weeks represented the interval between injections, and
was therefore the earliest point at which treatment
could be re-evaluated. Another possible explanation for
why the predictive accuracy seen in this study of olanza-
pine LAI was better than that seen in studies of oral
antipsychotics is that with depot formulations, adher-
ence is guaranteed at least through the injection interval.
Adherence to oral antipsychotics is not assured. Study
populations containing a mix of patients with varying
degrees of adherence may have lowered the predictive
accuracy of early response/non-response in those
studies.
A comparison of rates of study discontinuation between
Early Responders and Early Non-responders was included
in this analysis because this outcome is associated with
increased rates of relapse and psychiatric hospitalization,
decreased functional outcome and quality of life, and
increased treatment costs [15,18-22]. Moreover, in a
response trajectory analysis, treatment response was
closely aligned with discontinuation rates [23]. While the
relationship between short-term and longer-term persis-
tence with therapy and the clinical significance of short-
term persistence are not known, results presented here
suggest that differences in efficacy noted as early as Week
2 may be an important determinant of short-term persis-
tence with treatment.
Early Responders to olanzapine LAI differed significantly
from Early Non-responders at baseline by having higher
PANSS Total scores. In prior studies of oral antipsychotics
for treatment of patients with chronic schizophrenia, Early
Responders also had higher baseline PANSS Total scores
than Early Non-responders,[6,7]. though this difference
was not found for patients with first-episode psychosis [9].
Other baseline discriminators between Early Responders
and Early Non-responders have been identified, including
differences in PANSS Positive [6,7]. and General Psycho-
pathology [6]. subscores. However, a difference in the
PANSS Negative subscore, as was seen in this study, had
not been noted previously. It appears that individuals with
higher levels of baseline psychopathology may have higher
likelihoods of responding to treatment, whether given
orally or in a depot formulation. Determining a cut-off for
the baseline PANSS score that maximized the predictive
value of this assessment tool could help clinicians optimize
treatment.
Early improvement in symptoms of schizophrenia in
response to olanzapine LAI not only predicted later
response in a total measure of symptoms of schizophre-
nia, but also predicted baseline-to-endpoint improvement
across multiple symptom domains and other measures of
quality of life, mental health, and social functioning. This
study highlights potential benefits to patients, clinicians,
families, and payers of early evaluation and identification
of patients responding poorly to treatment. These find-
ings echo those of Ascher-Svanum et al.,[4]. who found
that in a post hoc analysis of data from a 1-year, rando-
mized, open-label study of antipsychotic therapy for
treatment of schizophrenia, patients who demonstrated
response at Week 4 had greater improvement from base-
line to Week 8 in measures of mental health, emotional
role social functioning, physical functioning, vitality, and
a composite mental health score than those who did not
respond at Week 4. Likewise, in a randomized, double-
blind, flexible-dosed, prospective 12-week study of people
with schizophrenia treated with oral risperidone therapy,
patients with ≥20% improvement on the PANSS Total
score by Week 4 of treatment achieved significantly
greater baseline-to-Week 12 improvement across all
functional subdomains of the Schizophrenia Objective
Functioning Instrument, a validated functional measure
including subdomains of living situation, instrumental
activity, productive activity, and social functioning [7].
Of the patients who did not meet criteria for response
at Week 4, 1 in 4 went on to meet the criteria for
response at Week 8. A regression model to identify char-
acteristics that distinguish Early Non-responders who do
a n dd on o tr e s p o n da tas u b s e q u e n tt i m ep o i n tf o u n d
that lack of early improvement in 2 PANSS subscale
scores - Negative Symptoms and Disorganized Thoughts
- predicted continued non-response at endpoint. Specifi-
cally, lack of at least a 3-point drop in the Negative sub-
scale score and lack of at least a 3-point drop in the
Disorganized Thoughts subscale score at 4 weeks pre-
dicted continued non-response. Using this secondary
predictive model as a confirming diagnostic test, lack of
subsequent response could be predicted with near cer-
tainty (NPV = 91%). This secondary prediction model
could potentially help in situations where clinicians need
reassurance before proceeding with a change in treat-
ment strategy.
This analysis had several limitations that should be
noted. First, it focused on a sample that consisted predo-
minantly of inpatients who were acutely, markedly ill at
b a s e l i n ea n dh a dah i s t o r yo fm u l t i p l er e l a p s e s .R e s u l t s
cannot be extrapolated to patients with less severe symp-
tomology or who are earlier in their course of illness.
This analysis used data from a trial that was 8 weeks in
length. Further study is needed to assess this phenom-
enon over a longer treatment period. Also, the 30-item
PANSS used to assess early response/non-response is a
lengthy measure that is not used in usual clinical prac-
tice, thus potentially limiting the clinical applicability
of our findings. However, we have recently identified
6 PANSS items that can be used to reliably assess
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slight loss in predictive accuracy [24]. Whether an abbre-
viated assessment such as this can be used to predict
longer term response based on early response to olanza-
pine LAI will need to be determined. Finally, the early
and substantial improvement seen in patients with the
m o r es e v e r ep a t h o l o g ya tb a s e l i n em a yb es i m p l er e g r e s -
sion toward the mean, but this is a limitation of all ana-
lyses of this type.
Conclusions
In the course of treatment of acutely ill patients with
schizophrenia, early response to olanzapine LAI was
found to predict later response with a high degree of
accuracy, similar to that seen with oral antipsychotics.
Although patient demographics were not helpful in dis-
tinguishing Early Responders from Early Non-responders,
greater baseline symptom severity, particularly in the
depressive and negative symptom domains, did help
identify those patients more likely to respond early.
Future analyses may want to further examine the predic-
tive value of these factors, as they have utility in identify-
ing response trajectories, as well [25]. Nearly one quarter
of patients who did not meet criteria for response at
Week 4 demonstrated response by Week 8. Patients who
lacked early improvement (at Week 4) in Negative Symp-
toms and Disorganized Thoughts were more likely to
continue being non-responders at Week 8. Compared to
Early Non-responders, the Early Responders were not
only more likely to respond to continued treatment with
olanzapine LAI, but were also more likely to experience
greater improvements in functional outcomes and persist
longer on therapy. An early response to antipsychotic
medication may serve as an early clinical marker that
clinicians can use when balancing the benefit and risk of
treatment with olanzapine LAI for acutely ill patients
with schizophrenia.
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